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CYCLOOXYGENASE-2 EXPRESSION IN POST-MASTECTOMY CHEST WALL RELAPSE.
Janet H. Kim1, Veerle Bossuyt2, Teresa Ponn3, Donald Lannin3, Bruce G. Haffty4. Departments of
Therapeutic Radiology1, Pathology2, and Surgery3, Yale University School of Medicine, New
Haven, Connecticut and Department of Radiation Oncology4, Robert Wood Johnson Medical
School, New Brunswick, New Jersey.
The purpose of this study was to assess the prognostic significance and clinical correlations of
cyclooxgenase-2 expression (COX) in a cohort of patients treated with radiation (RT) for postmastectomy chest wall relapse (PMCWR). Between 1975 and 1999, 113 patients were treated for
isolated PMCWR. All patients were treated with biopsy and/or excision of the CWR followed by
RT. Median follow-up was 10 years. All clinical data including demographics, pathology, staging,
receptor status, HER-2/neu status, and adjuvant therapy were entered into a computerized
database. Paraffin-embedded CWR specimens were retrieved from 42 patients, of which 38 were
evaluated, created into a tissue microarray, stained by immunohistochemical methods for COX,
and graded 0-3+. A score of 2-3+ was considered positive. Overall survival from original
diagnosis for the entire cohort was 44% at 10 years. Survival rate after chest wall recurrence was
28% at 10 years. The distant metastasis-free survival rate after CWR was 40% at 10 years. Localregional control of disease was achieved in 79% at 10 years after CWR. COX was considered
positive in 13 of 38 cases. COX was inversely correlated with ER (p= .045) and PR (p = .028),
and positively correlated with HER-2/neu (p =.003). COX was also associated with a shorter time
to PMCWR. The distant metastasis-free rate for COX negative patients was 70% at 10 years,
compared with 31% at 10 years for COX-2 positive patients (p = 0.029). COX positive had a
poorer local-regional progression-free rate of 19% at 10 years, compared with 81% at 10 years for
COX negative (p = 0.003). Outcome following RT for PMCWR is relatively poor. Positive COX
correlated with other markers of poor outcome including a shorter time to local relapse, negative
ER/PR and positive Her-2/neu status. Positive COX correlated with higher distant metastasis and
lower local-regional control of disease. If confirmed with larger studies, these data have
implications with respect to the concurrent use of COX-2 inhibitors and radiation for PMCWR.
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INTRODUCTION
Breast cancer is the leading cancer among women and the second most
common cause of cancer death in women after lung cancer. It is the main cause of
death in women ages 45 to 55. (1) Breast cancer rates have increased by 1.2 % per year
from 1940 to 1980. Each year, approximately 180,000 American women are
diagnosed with breast cancer and 40,000 die from the disease. (1) Although the most
important risk factor for the development of breast cancer is age, risk may be affected
by age at menarche, first pregnancy, age at menopause, use of exogenous estrogens,
and family history. A variety of pathologic findings may be discovered at the time of
diagnosis, but the most important distinction from the standpoint of treatment has been
between invasive and non-invasive (in situ) cancer. Invasive (infiltrating) ductal
carcinoma is the most common type of breast cancer, while ductal carcinoma in situ
(DCIS) comprises approximately 15-20% of all breast cancer. Although early
detection and improved treatment modalities over the years have increased survival
rates, extensive efforts have been directed at improving outcomes with more targeted
therapies. Various factors may affect the treatment of localized breast cancer. These
include the size and extent of the tumor, spread of cancer to lymph nodes, tumor
markers, and hormone receptors. Current treatment options for breast cancer are often
integrated into a multi-modality approach by including various combinations of
surgery, chemotherapy, hormone therapy, and radiation therapy. Regarding
chemotherapy, anthracycline-based regimens are often chosen due to their significant
benefit compared to nonanthracycline-containing adjuvant chemotherapy such as
cyclophosphamide, methotrexate, plus fluorouracil, or CMF.(1) Surgery may involve

2
mastectomy or lumpectomy (breast-conserving surgery) with or without lymph node
dissection. Lumpectomy is usually accompanied by radiation therapy to the entire
breast. Despite the increasing use of breast conserving surgeries for breast cancer,
mastectomy still plays a large role in primary and salvage treatment.
Unfortunately, despite the attempted removal of all breast tissue during a
mastectomy, local-regional recurrences (LRR) still occur. About 10-20% of all
patients develop a local recurrence, mostly within the boundaries of the chest wall,
within a 10 year period despite achieving negative surgical margins. (2-9) Boundaries
of the chest wall extend from the supraclavicular line to the diaphragm, and from the
sternum to the mid-axillary line. Local-regional recurrence may occur in the skin,
subcutaneous tissue, muscle, or bone of chest wall. The three most common sites of
local-regional recurrence in decreasing order are the chest wall, supraclavicular
region, and axilla. The most frequent site for recurrence in the chest wall is in the scar
or grafted area from previous mastectomy. Most local recurrences occur within a 3
year period after mastectomy. (10)
Local-regional recurrences are significant because they often cause
considerable morbidity and distress to patients. A recurrence may present as a rashlike lesion, induration, nodule or ulcer. Poor circulation and relatively rapid tumor
growth may prolong healing time for lesions such as ulcers. In one study by
Bedwinek et al, 62% of patients with uncontrolled LRR experienced one or more of
the following problems: bleeding and/or ulceration, pain, arm edema, and brachial
plexus paralysis.(11)
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Another study by Bedwinek et al attempted to identify the natural history after
LRR and to identify clinical factors that would predict which subsets of patients would
have a good prognosis.(12) A retrospective study was performed of 129 patients with
chest wall relapse after mastectomy who then received radiation only, excision only,
or both. Factors that determined good prognosis were single recurrence, size of largest
recurrence less than 1 cm, and a disease-free interval of greater than 2 years. All of
these factors had a significant effect on disease-free survival and overall survival.
Overall survival and disease-free survival at 5 years from primary diagnosis were
found to be 36% and 13% respectively, while 81% of patients eventually developed
distant metastases. The time to develop distant metastases was longer for patients
with good prognostic factors.
A large study performed by Recht et al in 1999 demonstrated the correlation
between the number of positive nodes and tumor size at the time of primary diagnosis
to incidence of local-regional failure. (13) Among patients with 1-3 positive lymph
nodes at primary diagnosis, the 10-year cumulative incidence of isolated localregional failure increased with increasing tumor size. Among patients with T2 stage,
the 10-year cumulative incidence of local-regional failure more than doubled between
those who had 1 to 3 positive lymph nodes compared to those who had 4 to 7 positive
lymph nodes. These results show that the incidence of local-regional failure was
positively correlated with number of positive lymph nodes and tumor size.
Treatment for chest wall relapses often consists of surgical excision when
feasible followed by radiation therapy to the area of recurrence. Patients are treated up
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to 50 Gy for completely excised recurrent tumors. For unresected lesions, 60-65 Gy is
given for lesions less than 3 cm while 65-75 Gy is given for lesions greater than 3 cm.
Prognosis is poor for patients who develop a chest wall relapse. Five-year
postrecurrence survival rates range from 36% to 53% (4, 5, 9, 12, 14-19) while disease-free
survival rates range from 13% to 44%.(4, 12, 16, 18, 19) Thus, these women represent a
high-risk subgroup with respect to systemic recurrence and mortality. In addition to
this, these patients also face significant morbidity as stated before due to the
aggressive nature of their tumors. Although various clinical and pathological
parameters have been indicated as prognostic factors for disease-free and overall
survival after local-regional recurrence, there is a need to examine molecular markers
as prognostic tools to aid clinical management.
One molecular marker that has been the subject of active research is
cyclooxygenase-2 (COX-2). COX-2 has been identified as a tumor marker associated
with poor prognosis in various cancers based on epidemiological, preclinical and
translational studies. Cyclooxygenase is a well-known enzyme in the inflammatory
pathway that catalyzes the conversion of arachidonic acid to prostaglandin H2, the
rate-limiting step in the formation of prostaglandins from membrane phospholipids.
There are two forms of cyclooxygenase: COX-1 and COX-2. COX-1 is known to be
constituitively expressed in a variety of mammalian cells. Its role has been linked to
physiological functions such as the cytoprotection of the stomach and control of
platelet aggregation.(20) In contrast, COX-2 is thought to be upregulated in response to
growth factors, tumor promoters, cytokines, and several oncogenes.(21-23)
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Active research has been directed at exploring the association between COX-2
and carcinoma. As a result, COX-2 has been found to be overexpressed in various
cancers such as lung, cervical, head and neck, colon, and pancreas. (24-29) One study
evaluated the prognostic significance of elevated COX-2 expression in a cohort of
primary resected lung adenocarcinomas.(24) A significant relationship was established
between increased COX-2 expression and shortened patient survival only in a cohort
of patients with stage I disease (p = 0.034). In one study by Gaffney et al, increased
expression of COX-2 was found to be associated with poorer overall and disease-free
survival in a cohort of cervical carcinoma patients treated with definitive radiation
therapy.(28) Another study evaluating squamous cell carcinoma of head and neck
cancers (HNSCC) demonstrated that mean levels of COX-2 mRNA were increased by
nearly 150-fold in HNSCC compared with normal oral mucosa from healthy
volunteers.(30) A study evaluating pancreatic cancers demonstrated increased
expression of COX-2 protein in pancreatic carcinomas compared to benign tumors. (29)
Knocking out the COX-2 gene in murine models of familial adenomatous polyposis
was shown in a study by Oshima et al to decrease the number and size of intestinal
polyps.(31) Expression of COX-2 has also been studied in human transitional cell
carcinoma of the urinary bladder.(32) COX-2 immunoreactivity was detected in 66% of
the carcinomas, whereas only 25% of the non-neoplastic samples were positive (p <
0.005).
Furthermore, there has been increasing evidence of the role of COX-2 in
breast cancer. COX-2 is expressed in about 40% of human breast cancers, and is
associated with poor prognosis.(33) The possible role of COX-2 in breast cancer was

6
first noted when elevated levels of prostaglandins were found in breast tumor cells.(3436)

A study in rat models subsequently demonstrated that forced overexpression of

COX-2 induced breast cancer.(37) Translational studies have also confirmed the
positive correlation between these two parameters. Ristimaki et al found that 37.4% of
invasive cancers analyzed by immunohistochemistry were found to have positive
COX-2 expression. In another study, 43% of invasive cancers and 63% of ductal
carcinomas in situ (DCIS) were found to stain positively for COX-2 by
immunohistochemical methods.(38) Positive COX-2 expression has also been
correlated with decreased distant disease-free survival, large tumor size, high
proliferation rate, and human epidermal growth factor receptor 2 (HER-2) gene
amplification.(20) These studies suggest that COX-2 inhibition may play a potential
role in breast cancer treatment.
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STATEMENT OF PURPOSE
The main objective of this analysis was to retrospectively determine whether a
significant correlation exists between positive COX-2 expression at the time of chest
wall recurrence and prognosis for post-mastectomy breast cancer patients using tissue
microarray analysis. Prognosis was determined by percentage of overall survival,
distant metastasis-free survival, and local-regional progression-free survival.
Secondary objectives were to examine the relationship between COX-2 expression
and time to post-mastectomy chest wall relapse, and ER, PR, and HER-2/neu status at
the time of local-regional recurrence.

8
PATIENTS and METHODS
A retrospective review was conducted of 113 patients who were treated with
radiation therapy for chest wall recurrence at the Yale University Department of
Therapeutic Radiology between 1979 and 1999. All patients had an isolated chest
wall recurrence without evidence of distant metastases at the time of presentation.
Patients who presented with primarily lymph node metastases, patients with
simultaneous distant metastases, and patients who received prior radiation therapy
were excluded from the analysis.
Patients underwent surgical excision of the local-regional recurrence when
feasible, followed by external beam radiation therapy. Standard radiation treatments
were given, and patients were treated to a total median dose of 60 Gray (Gy) to the
chest wall. Nineteen patients received radiation treatment to the chest wall only, and
the remaining patients received radiation to the chest wall and regional lymphatics.
Adjuvant chemotherapy and hormone therapy were administered as deemed necessary
by physicians. Forty patients received chemotherapy, and 56 patients received
hormonal therapy. The median follow-up after treatment for recurrence was 10.13
years.
Patient charts were reviewed for demographics and radiation therapy
parameters. Other data including clinical and pathologic staging of initial tumor,
method of detection, lymph node status, histologic parameters, surgery performed,
adjuvant treatment for the initial tumor, estrogen receptor status, progesterone receptor
status, chest wall progression, distant metastases, disease-free survival, and overall
survival were documented. All data were entered into a computerized database. The
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protocol for chart review and processing of tumor specimens was approved by the
Yale School of Medicine Human Investigations Committee.
Tumor blocks from chest wall recurrence specimens were successfully
collected from 42 patients, of which 38 were evaluable for tissue microarray analysis.
The tissue microarray was created by taking core needle sections from existing tumor
blocks and arranging them into a common paraffin block. This recipient paraffin
block was prepared with 2-fold redundancy, which denotes acquiring two samples
from each of the pre-existing paraffin-embedded tumor specimens. Two-fold
redundancy has been shown to correlate well with conventional immunohistochemical
staining. One study determined that analysis of two cores was comparable to analysis
of a whole tissue section in greater than 95% of cases.(39) It has also been
demonstrated that many proteins in archival tissue retain their antigenicity for greater
than 60 years, thus validating the use of these tissues in microarray analysis.
Cores were initially made in the recipient block to allow placement of tumor
specimens. Core depths were made at approximately 2-3 mm while diameters were
set at 0.6 mm. “Biopsies” were then taken from the donor block and then placed into
the cores of the recipient block. These were performed until specimens from all 38
patients were placed into the recipient paraffin block. The block was then incubated at
37 degrees for 10 minutes to allow the cores to adhere to the walls of the holes in the
array. The array block was then placed into a microtome for sectioning and cut 5 uM
thick with a tape-based tissue transfer system (Intrumedics, Hackensack, NJ, U.S.A.)
After each section was placed on Paraffin Sectioning Aid (PSA-4X) adhesive coated
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slides, they were radiated with UV light for 20 seconds. The slide was then placed in
xylene for 60 seconds and allowed to air dry.
Analysis by immunohistochemistry was performed on microarray slides after
deparaffinization in xylene followed by 100% ethanol. Samples were then pretreated
to promote antigen retrieval with the DAKO Target Retrieval Solution (DAKO,
Carpinteria, CA, U.S.A.) A 3% hydrogen peroxide solution was then used for
endogenous peroxidase blocking. Slides were then incubated with monoclonal
antibody COX-2 (Cayman Chemical, Ann Arbor, MI, U.S.A.; #160112; dilution 1:50)
After incubation, the slides were washed in phosphate buffered saline, and a
biotinylated secondary antibody was applied. Samples were then applied with DAKO
streptavidin-horseradish peroxidase using LSAB + Kit. DAKO DAB (3,3diaminobenzidine tetrahydrochloride dehydrate) was then applied as a chromogenic
substrate. Tissue microarrays were also stained for HER-2/neu, ER, and PR from a
previous study that used patients from a similar cohort as this study to create a
microarray.(40)
Analysis of the tissue staining was performed by a single pathologist (V.B.)
and one of the authors who were both blinded to patient outcome. Both distribution
(percentage of tumors stained) and intensity of the cytoplasmic staining were
documented. Intensity was recorded on a scale of 0 to 3+ with 3+ having the strongest
intensity. The specimens were then given a positive or negative score based on the
intensity and distribution scores. Any score with 2 or 3+ with a distribution of >10%
was considered positive in this study, in accordance with standard clinical practices.(41)
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These data were added to the computerized database with all clinical and pathologic
outcomes variables.
Chart review for data collection, collection of chest wall recurrence tissue for
tissue microarray analysis, and reading of slides with pathologist for scoring were
performed by the student. Creation of tissue microarray and staining of prepared
slides by Cox-2 antibody were performed by the tissue microarray lab and
immunohistochemistry lab respectively at Yale University School of Medicine.
The Prodas Data Base System (Conceptual Software, Houston, TX) was used
to assess patient data and statistics. The Cox regression model was used to test
clinical and pathologic factors by both univariate and multivariate analysis. The lifetable method was used to calculate survival curves and the Mantel-Hanszel chi-square
test to measure differences in survival curves. This generation of data was performed
by the thesis advisor.
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RESULTS
One hundred thirteen patients presented to the Department of Therapeutic
Radiology at Yale-New Haven Hospital between January 1979 and December 1999
for radiation treatment to their chest wall for local-regional recurrence of breast
cancer. The mean +/- standard deviation (SD) age at initial diagnosis for these 113
patients was 52.3 years +/- 13.7 years. The mean +/- SD age at presentation with a
first isolated chest wall recurrence was 56.9 years +/- 14.5 years. The mean time to
the initial chest wall recurrence was 4.6 years. The median follow-up after initial
diagnosis was 13.7 years, and the follow-up after treatment for local-regional
recurrence was 10.1 years.
Of 113 patients, 98 were Caucasian, 10 were African American and 5 were
from other racial groups. All patients received simple, modified, or radical
mastectomy for their initial tumor. The mean +/- SD size of the tumor at initial
diagnosis of breast cancer was 3.3 cm +/- 2.1 cm. The mean number of axillary lymph
nodes sampled was 14.4 +/- 9.2 lymph nodes, with a mean +/- SD of 3.7 +/- 6.9
positive lymph nodes. Half of the patients (n = 57) received adjuvant chemotherapy
and 33 patients received adjuvant hormone therapy at the time of diagnosis of their
original breast carcinoma. The mean +/- SD time between initial diagnosis and chest
wall recurrence was 4.6 years +/- 4.6 years. Within 5 years, 66% of patients had
experienced their recurrence; and, by 10 years, 90% of patients had developed a
recurrence. At the time of chest wall relapse, the mean +/- SD size of the recurrence
tumor was 1.6 cm +/- 1.0 cm (median, 1.5 cm; range, 0.5-5.0 cm; n = 78). Clinical
outcomes for entire patient population are summarized in Table 1. Overall survival
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after original diagnosis was 69% at 5 years and 44% at 10 years. Overall survival
after chest wall recurrence was 46% at 5 years and 28% at 10 years. The distant
metastasis-free rate for all patients after chest wall recurrence was 49% at 5 years and
40% at 10 years. Local progression-free survival after chest wall recurrence was 83%
at 5 years and 79% at 10 years.
Table 2 summarizes the demographic, staging, receptor status, and treatment
parameters at both initial diagnosis and time of chest wall relapse for the cohort of 38
patients included in the tissue microarray. Mean age at diagnosis was 56.7 years with a
range from 35-92 years. Pathologic T status at the time of primary diagnosis was
found to be predominantly T2 with the second most common status being T3. Patients
were also predominantly found to have negative lymph node status at the time of
original diagnosis (23/38). There was one patient with unknown lymph node status.
Estrogen and progesterone receptor status were approximately equally distributed
among positive, negative, and unknown status. The majority of patients received
modified radical mastectomy at the time of primary diagnosis (34/38) as opposed to
total mastectomy (3/38) or radical mastectomy (1/38). At the time of chest wall
relapse, patients predominantly underwent excisional biopsy (33/38). Most patients
also did not receive chemotherapy at the time of recurrence (30/38), although most
received hormone therapy (25/38). There were no significant differences between this
selected cohort of 38 patients and the overall group of 113 patients with respect to the
major clinical characteristics and outcomes. The 5-year overall survival after primary
diagnosis of all patients (n=113) was 69% while those in the array (n=38) was 78%.
The 5-year distant metastases-free survival after primary diagnosis was 69% of all
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patients compared to 67% of those in the array. Finally, the 5-year local progressionfree survival after chest wall relapse was 83% for all patients compared to 73% of
those in the array.
Cox-2 staining was predominantly cytoplasmic. Using the criteria of 2-3+
staining in greater than 10% of cells, 13 of 38 (34%) were considered positive. The
majority of patients underwent complete excision of their recurrence tumors (33/38).
Those who underwent biopsy were in complete remission following external beam
radiation therapy. Only 8/38 patients received adjuvant chemotherapy while 25/38
patients were known to receive hormone therapy at the time of chest wall relapse.
There were no significant differences in treatment (surgery, chemotherapy or
hormonal therapy) as a function of COX-2 status (Table 3). Among patients with
positive COX-2 status, 12 of 13 (92%) received an excisional biopsy at the time of
chest wall relapse while among those with negative COX-2 status, 21 of 25 (84%)
underwent this procedure. Nine of 13 (69%) of positive COX-2 patients received
hormone therapy at the time of chest wall relapse while 16 of 22 (73%) of negative
COX-2 patients received this therapy. Finally, 3 of 13 (23%) of positive COX-2
patients received chemotherapy at chest wall relapse while 5 of 25 (20%) of negative
COX-2 patients underwent this route.
Correlation of COX-2 expression with various molecular markers, disease-free
interval, and chest wall progression is summarized in Table 4. COX-2 expression was
found to be positively correlated with HER-2/neu status, early time to chest wall
recurrence, and chest wall progression. All were statistically significant. When HER2/neu status was analyzed, 9 of 14 patients (64%) with positive HER-2/neu status had
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positive COX-2 expression. This compares with only 5 of 14 patients (36%) with
positive HER-2/neu status who had negative COX-2 expression. In regards to time to
chest wall recurrence, patients were divided into two groups of early recurrence and
late recurrence. Early recurrence was defined as <24 months. Seven of 11 patients
(64%) who tested positive for COX-2 demonstrated early recurrence while only 6 of
27 patients (22%) who tested positive for COX-2 showed late recurrence. In chest
wall progression analysis, 7 of 11 (64%) of patients who tested positive for COX-2
expression developed another chest wall recurrence after treatment for their original
chest wall relapse, while 6 of 27 (22%) of positive COX-2 patients did not.
COX-2 expression was negatively correlated with both ER and PR status, both
with statistical significance. When ER status was analyzed, 5 of 23 (22%) of patients
with positive ER status demonstrated positive COX-2 expression. This was in
contrast to 18 of 23 (78%) of patients with positive ER status demonstrating negative
COX-2 expression. In regards to PR status, only 2 of 15 (13%) of patients with
positive PR status demonstrated positive COX-2 expression while 13 of 15 (87%)
demonstrated negative COX-2 expression.
Evaluations of COX-2 expression in relation to outcomes are summarized in
Table 5. It is worth noting that the 5-year distant metastases-free rate after primary
diagnosis for COX-2 negative patients was 79% while the rate for COX-2 positive
patients was 41% (Figure 1). This was significant with a p-value of 0.029. The five
year local progression-free rate for COX-2 negative patients was 87% while the rate
for COX-2 positive patients was 38% (Figure 2). This was highly significant with a pvalue of 0.003.
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A multivariate model, taking into account all molecular markers (Her-2/neu,
ER, and PR), as well as time to recurrence was performed on the 38 patients. COX-2
overexpression was still found to be a significant predictor of chest wall progression
(HR = 4.91; CI = 1.09-22.1; P = 0.038). In the analysis for distant metastases free
survival, significant predictors were COX-2 expression (HR = 5.25; CI = 1.44-19.2; P
= 0.01) and positive HER-2/neu status (HR = 0.22; CI = .054-0.92; P = 0.038). PR
status demonstrated borderline significance (HR = 0.29; CI = 0.075-1.12; P = 0.073).

17
DISCUSSION
Despite receiving treatment for local-regional recurrence after mastectomy,
prognosis is poor for these patients and much research has been directed at
determining the factors that lead to this poor prognosis. The location, extent and size
of recurrence, number of recurrences, number of recurrence nodules, primary lymph
node status, ER status of primary, ER and PR status of recurrence, and age at time of
recurrence have all been reported to be indicators of prognosis.(4, 5, 9, 12, 17-19) A large
number of studies have reported that the most significant factor for distant metastases
and survival is the disease-free interval, or interval to recurrence from primary
diagnosis. Decreased disease-free interval, or early recurrence has been associated
with ultimately poor outcome in the majority of these studies.(4, 5, 9, 12, 17-19, 42, 43)
Despite these clinical and pathological prognostic parameters, there is a need to
determine molecular markers to more accurately guide clinical management.
Unfortunately, it has been difficult to accrue an adequate number of patients for large
prospective randomized studies following women after chest wall recurrence. As a
result, Haffty et al conducted a retrospective study in order to explore the prognostic
significance of estrogen receptor, progesterone receptor, p53, HER-2/neu, and cyclin
D at chest wall relapse. Significant factors for distant metastasis after local recurrence
were time to recurrence and PR status, and for local-regional disease progression was
HER-2/neu status.(40) The distant metastasis-free survival rate for patients with
positive PR status was 84%, compared to 38% in those with negative PR status.
Patients with positive HER-2/neu status had a local-regional progression-free rate of
59% while patients with negative HER-2/neu status had a rate of 92%. Additional
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biological markers need to be assessed to more clearly define prognosis and assist the
physician in selecting therapy regimens catered for high-risk patients. One marker
that has been the focus of active investigation is COX-2.
In our study, a uniform cohort of patients who developed chest wall relapse
and received radiation therapy were selected to assess the prognostic significance of
COX-2 after relapse. Although there was no significant difference in overall survival
between COX-2 positive and negative patients, patient numbers were relatively small
to detect survival differences. The resulting analysis demonstrated that patients who
overexpressed COX-2 had a lower chance of being free of distant metastases and
higher chance of chest wall progression both on univariate and multivariate analysis.
Patients with positive COX-2 expression had a 5-year distant metastases-free rate of
41% while those with negative COX-2 expression had a rate of 79% after primary
diagnosis. The results of the 5-year local progression free rate was even more
significant at 38% with positive COX-2 expression and 87% with negative expression.
These poor prognostic findings are consistent with a previous study that found the
distribution and intensity of COX-2 expression from tissue microarray analysis to
correlate significantly with diminished disease-free survival in breast cancer patients,
although in this study COX-2 also correlated with decreased overall survival.(44)
Paraffin-embedded tumor specimens from 23 women with invasive cancer were
stained for COX-2 expression. The 5-year overall survival rate was 100% for patients
with less than 75% of breast cancer cells expressing COX-2 protein compared with
49% for patients with greater than or equal to 75% expression (p = 0.044). The study
also found that younger patients with invasive breast cancer may have a greater
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percentage of COX-2 expression in their cancers. A significant association has also
been found between COX-2 overexpression and distant metastasis in breast cancer.(45)
In this study, archival specimens of human breast cancer (n = 29) were collected and
analyzed after staining with COX-2 antibodies. COX-2 overexpression occurred in
37.9% of their sample study. Previous studies have also demonstrated that positive
COX-2 expression is likely associated with poor outcome due to its correlation with
poor prognostic factors such as large tumor size, high histological grade, axillary node
metastases,(20) and lymphovascular invasion.(46) Furthermore in our study, COX-2
positivity more likely resulted in early local-regional recurrence, or time to recurrence
in less than 2 years (P = 0.015). This is significant because as stated before, early
recurrence has been associated with poor prognosis. COX-2 was also found to be
negatively correlated with ER (P = 0.045) and PR status (P = 0.028) at recurrence in
our analysis. This finding is consistent with two recent studies that also analyzed
COX-2 expression using tissue microarray analysis in breast cancer.(20, 46) Because
positive ER(47) and PR status(48) has been found to be associated with good prognosis,
this inverse association with these two markers most likely indicates poor prognosis
for this cohort of patients.
A marker that occurs in 20-30% of human breast cancers and has been
correlated with poor prognosis is HER-2/neu.(49-53) Press et al demonstrated that HER2/neu gene amplification in the absence of adjuvant therapy is an independent
predictor of poor clinical outcome and is a stronger predictor than tumor size. Patients
with small tumors who demonstrated HER-2/neu gene amplification were at increased
risk of recurrence and disease-related death.(51) Another study by Seshadri et al
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concluded that HER-2/neu amplification is an independent predictor of shorter
disease-free survival in both node-negative and node-positive patients.(52) Our results
demonstrated that COX-2 expression was positively correlated with HER-2/neu status
(P = 0.003), thereby indicating poor prognosis. Other studies have also confirmed a
positive correlation between these two markers. Two recent studies showed that
elevated COX-2 expression was correlated with the presence of HER-2 oncogene
amplification in human breast cancers.(20, 54) Howe et al demonstrated that treatment
with celecoxib, a COX-2 inhibitor, significantly reduced the incidence of mammary
tumors in mice overexpressing wild-type neu protein and caused about a 50%
reduction in mammary prostaglandin E2 (PGE2) levels. Because mammary glands
from these mice models expressed all four PGE2 receptor subtypes, it was suggested
that signaling through PGE2 receptor subtypes is important for the development of
mammary tumors.(55) Benoit et al further showed that COX-2 inhibition reduced
HER-2/neu proteins levels and acted synergistically with trastuzumab, an anti-HER-2
monoclonal antibody in breast cancer cell lines.(56) Concurrent administration of
COX-2 inhibitors and HER2/neu antibodies for treatment experimental colorectal
cancer inhibited tumor growth more effectively than when either was administered
alone.(57)
More pertinent to our study is the possibility that COX-2 expression may be
involved with decreased radiosensitivity during treatment of recurrence. Other studies
have shown this relationship between COX-2 and radiosensitivity. In vitro studies
demonstrated that a selective COX-2 inhibitor, SC-236, in glioma tumor cell culture
medium enhanced cell killing by ionizing radiation. When administered in
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combination with local radiation, SC-236 caused a greater than additive increase in
tumor growth delay.(58) Two recent reports concluded that SC-236 markedly increased
tumor radioresponse in NFSA(59) and FSA sarcoma(60) bearing mice without greatly
affecting normal tissue radioresponse. Other studies have shown that prostaglandins
may serve as radioprotectors.(61) Although the mechanism is not well understood, it is
thought that prostaglandins may protect cellular repair mechanisms(62) or inhibit
radiation-induced apoptosis. Additional studies should be performed to elucidate the
association of COX-2 expression and diminished radiosensitivity.
The methods in our study included use of tissue microarray, which was
composed of 0.6 mm cores from original tissue specimens. The validity of using these
cores to represent larger tissues has been confirmed in a variety of cancers such as
head and neck, lung, and breast.(39, 63, 64) An advantage to using this technique was that
all specimens were processed simultaneously using the same conditions during
immunohistochemistry, thus resulting in experimental uniformity. Tissue specimens
collected at chest wall relapse were relatively homogeneous. Chest wall specimens
were only collected from patients who did not present with simultaneous distant
metastases. A monoclonal COX-2 antibody was used which may have improved
specificity for COX-2 compared with a polyclonal antibody.
There were also some limitations to this study. Although the method of
immunohistochemistry is relatively fast and readily available in most pathology
departments, it is a test subject to interobserver variability. The reading of stained
microarray slides is also subjective and may result in variability among pathologists.

22
Other limits of this study included its retrospective design and relatively small sample
size. Additional studies need to be carried out to validate these findings.
Due to the poor prognosis associated with increased COX-2 expression in
tumors, COX-2 inhibitors as potential therapeutic targets remain an active area of
research. Various selective COX-2 inhibitors have been shown to slow tumor growth
in experimental animals.(65, 66) Kishi et al reported that SC-236 was found to inhibit
tumor growth on its own, decrease PGE2 levels in sarcoma FSA tumors, and inhibit
neoangiogenesis. One study showed that NS-398, a COX-2 selective inhibitor,
induced apoptosis in colorectal tumor cells which was independent of COX-2 protein
expression.(67) Celecoxib has been shown to decrease tumor size when compared to
control groups in rat models.(68) In another study by Masferrer et al, COX-2 was found
to suppress tumor growth by inhibiting angiogenesis. COX-2 was detected in the
angiogenic vasculature in most of human colon, prostate, lung, and breast tumors. In
addition, celecoxib dose-dependently inhibited tumor growth and the number and size
of lung metastases in two animal models of Lewis lung carcinoma and the human
colon carcinoma HT-29. It is noteworthy that the expression of COX-2 in these
models was mainly limited to the angiogenic blood vessels, the preexisting vasculature
adjacent to the primary tumor, and the blood vessels invading the metastatic lesions,
and not the cancer cells themselves. In the same study, celecoxib was also a potent
inhibitor of angiogenesis in the rat corneal model.
Numerous mechanisms have been proposed attempting to elucidate the
correlation between COX-2 expression and tumorigenesis. One theory suggests that
COX-2 catalyzed products such as prostaglandins may directly break down into a
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mutagen and form adducts with deoxynucleosides.(69) Prostaglandins, more
specifically PGE2, are also known to be potent immunosuppressants. PGE2 blocks the
anti-tumor activity of macrophages and natural killer cells,(70, 71) and inhibits
production of cytotoxic lymphokines. These activities may block natural surveillance
mechanisms to inhibit tumor growth and spread. COX-2 has also been hypothesized to
induce carcinogenesis through regulation of apoptosis. Rat intestinal epithelial cells
transfected with COX-2 showed increased adhesion to extracellular matrix, resistance
to butyrate-induced apoptosis, and elevated expression of bcl-2, a protein which
inhibits apoptosis.(72) COX-2 may also affect tumorigenesis by dysregulating cell
growth. It has been proposed that increased duration of G1 phase of the cell cycle
may cause resistance of cells that permanently express COX-2 to undergo
programmed death.(73) It has also been suggested that COX-2 is correlated with
angiogenesis. COX-2 showed a significant linear correlation (P = 0.001) with staining
of CD31, an endothelial cell marker of angiogenesis in breast cancer tissue.(74) CD31,
which is also known as platelet-endothelial cell adhesion molecule-1, is thought to
play a role in various endothelial cell functions including angiogenesis, migration, and
transmigration of leukocytes across endothelium. This correlation with angiogenesis
is significant because some studies have suggested that angiogenesis may be inversely
associated with survival.(75)
In conclusion, our study showed that for patients who develop a local-regional
recurrence after mastectomy, positive COX-2 expression at the time of recurrence is a
sign of poor prognosis. These patients have a lower chance of expressing favorable
prognostic markers such as ER and PR, and a higher chance of expressing poor
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prognostic markers such as HER-2/neu. In addition, they have a greater possibility of
local progression and distant metastases. These results may suggest that COX-2 may
play a role in decreased radiosensitivity at the time of local-regional relapse, and that
COX-2 inhibition with or without anti-HER2/neu therapy during chest wall radiation
may improve prognosis. More specifically, COX-2 inhibitors may provide a relatively
safe and inexpensive adjuvant to chest wall irradiation. Prospective randomized trials
with a large cohort of patients are needed to further assess these results.
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Table 1
Outcomes and Survival Data for 113 Patients
Endpoint
Actuarial
Actuarial rate
rate at 5 yrs
at 10 yrs +/- SE
+/- SE (%)
(%)
Overall survival
after chest wall
46 +/- 4.9
28 +/- 4.8
recurrence
Distant metastasisfree survival after
49 +/- 5.3
40 +/- 5.9
chest wall
recurrence
Local progressionfree survival after
83 +/- 3.6
79 +/- 4.1
chest wall
recurrence
SE: standard error
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Table 2
Clinical Characteristics of 38 Patients in Tissue Microarray
Characteristic
No. of
Mean
Range
patients
Age at diagnosis (yrs)
38
56.7
35-92
Follow-up from original
38
21.1
7-45
diagnosis (yrs)
T status at original diagnosis
Pathologic T status
T1
7
T2
17
T3
8
T4
1
Unclear original clinical T
5
status
Lymph node status at original
Dx
No. with positive lymph
14
nodes
No. with negative lymph
23
nodes
Unknown
1
Receptor status at original
diagnosis
Estrogen receptor
Positive
13
Negative
14
Unknown
11
Progesterone receptor
Positive
12
Negative
12
Unknown
14
Surgery performed
Total mastectomy
3
Modified radical
34
mastectomy
Radical mastectomy
1
Adjuvant systemic therapy
Hormone therapy
Given
11
None given
27
Chemotherapy
Given
12
None given
26
Surgery at CWR

35
Excisional biopsy
Incisional biopsy
Chemotherapy at CWR
Given
None given
Hormone therapy at CWR
Given
None given
Unknown

33
5
8
30
25
10
3
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Table 3
Correlation of Cox-2 with Clinical Characteristics of 38 Patients
Characteristic
Surgery at CWR
Excisional biopsy
Incisional biopsy
Hormone Therapy at CWR
Given
Not given
Chemotherapy at CWR
Given
Not given
CWR: chest wall relapse

COX-2 Pos

COX-2 Neg

12/13
1/13

21/25
4/25

9/13
4/13

16/22
6/22

3/13
10/13

5/25
20/25
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Table 4
Correlation of COX-2 with ER, PR, HER-2/neu, Time to CWR,
and Chest wall progression
COX-2: Pos COX-2:
P-value
Neg
ER Status
Pos
5/23 (22%)
18/23 (78%) 0.045
Neg
8/15 (53%)
7/15 (47%)
PR Status
Pos
2/15 (13%)
13/15 (87%) 0.028
Neg
11/23 (48%) 12/23 (52%)
HER-2/neu
Pos
9/14 (64%)
5/14 (36%) 0.003
Neg
4/24 (17%)
20/24 (83%)
Time to CW
Recurrence
Early (< 2 yrs)
7/11 (64%)
4/11 (36%) 0.015
Late ( > 2 yrs)
6/27 (23%)
21/27 (77%)
CW progression
Pos
7/11 (64%)
4/11 (36%) 0.015
Neg
6/27 (22%)
21/27 (78%)
ER = estrogen receptor; PR = progesterone receptor; Pos = positive;
Neg = negative; CW = chest wall
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Table 5
Correlation of COX-2 with Outcomes
Endpoint
COX-2
COX-2 P-value
Pos
Neg
Five yr survival after CWR 47
56
.32
(%)
Five yr distant mets-free
41
79
.029
rate after primary dx (%)
Five yr local progression38
87
.003
free rate after CWR (%)
Pos: positive; Neg: negative; yr: year; dx: diagnosis; CWR: chest
wall relapse; mets: metastases
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Figure 1. Distant metastasis free rate following chest wall relapse by COX-2.
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Figure 2. Local chest wall progression free rate by COX-2.

